Lara D. Veeken · 2022 · 17 citations · 22 references
MedicineInternal MedicineClinical Classification SystemsPulmonary Function TestingPulmonologyInterstitial Lung DiseaseInterstitial Lung Disease ImagingPulmonary AssessmentPulmonary Function AssessmentSystemic SclerosisDisease Severity EstimationDisease Severity PerceptionDisease SubsetsInterstitial Lung Disease AssessmentInterstitial Lung Disease ClassificationInterstitital Lung DiseaseLung Disease ProgressionLung Disease Severity Grading
OBJECTIVES: To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). METHODS: A conceptual framework for subclinical, clinical and progressive ILD was provided to 83 experts, asking them to use the framework and classify actual SSc-ILD patients. Each patient profile was designed to be classified by at least four experts in terms of severity and risk of progression at baseline; progression was based on 1-year follow-up data. A consensus was reached if ≥75% of experts agreed. Experts provided information on which items were important in determining classification. RESULTS: Forty-four experts (53%) completed the survey. Consensus was achieved on the dimensions of severity (75%, 60 of 80 profiles), risk of progression (71%, 57 of 80 profiles) and progressive ILD (60%, 24 of 40 profiles). For profiles achieving consensus, most were classified as clinical ILD (92%), low risk (54%) and stable (71%). Severity and disease progression overlapped in terms of framework items that were most influential in classifying patients (forced vital capacity, extent of lung involvement on high resolution chest CT [HRCT]); risk of progression was influenced primarily by disease duration. CONCLUSIONS: Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT.
22
Interrater reliability: the kappa statistic
Marry L. McHugh · Biochemia Medica · 2012 · 18.6K citations · Full text
Interrater reliability: the kappa statistic.
Mary L. McHugh · PubMed · 2012 · 9.2K citations · Full text
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Kevin R. Flaherty, Athol U. Wells, Vincent Cottin et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine · 2019 · 1.6K citations · Full text